This July, CATUG will be in Boston, joining two leading international conferences dedicated to RNA therapeutics, in vivo gene editing, and next-generation delivery technologies. Together with global biopharmaceutical innovators, researchers, and industry partners, we look forward to exchanging insights on engineering innovation, CMC strategies, and translational development for advanced therapeutics.

Conference 01

6th Annual mRNA-Based Therapeutics Summit
July 20–22 | Boston, USA

Bringing together leaders across the mRNA ecosystem, the summit will explore the latest advances in RNA therapeutics, with sessions covering delivery technologies, CMC development, analytical characterization, manufacturing scale-up, and clinical translation.

Conference 02

5th In Vivo Cell Engineering & Gene Editing Summit
July 28–30 | Boston, USA

Focused on the rapidly evolving field of in vivo cell engineering and gene editing, the conference will feature discussions on next-generation delivery platforms, genome editing technologies, CMC strategies, manufacturing solutions, and translational development for advanced therapies.

Featured Presentation

During both conferences, Dr. Mina Li, Director of Business Development, CATUG, will present:

Accelerating LNP-Based Pipelines: From Discovery to Clinical Proof-of-Concept and Beyond

The presentation will highlight CATUG's integrated development strategy spanning plasmid DNA, IVT RNA, and LNP formulation, demonstrating how engineering-driven CMC development accelerates early clinical translation.

Key topics include:

• Establishing and controlling Critical Quality Attributes (CQAs) under a Quality by Design (QbD) framework;
• Ensuring process robustness and consistency during manufacturing scale-up;
• Leveraging data-driven development strategies to support efficient technology transfer;
• Building continuous CMC packages that enable rapid progression from discovery to clinical Proof-of-Concept (PoC).

Drawing on CATUG's experience in GMP manufacturing and investigator-initiated trial (IIT) support, the presentation will illustrate how integrated process development and quality systems help reduce development risk while generating reliable CMC data to support future IND submissions and clinical advancement.

Engineering Advanced Therapeutics with an Integrated CRDMO Platform

As a specialized CRDMO for advanced therapeutics, CATUG provides an end-to-end development and manufacturing platform covering:

• High-quality plasmid DNA manufacturing;
• IVT production of mRNA, saRNA, and circRNA;
• Targeted LNP formulation and process development;
• Peptide and recombinant protein manufacturing;
• GMP aseptic Fill & Finish services.

Supported by scalable manufacturing technologies, rigorous quality systems, and global regulatory experience, CATUG helps partners streamline the journey from candidate selection to clinical Proof-of-Concept, delivering greater confidence throughout development and accelerating the path toward clinical translation.

Meet CATUG in Boston

Our team will be available throughout both conferences to discuss your development programs.

Whether you are advancing mRNA therapeutics, in vivo gene editing, or LNP-enabled delivery platforms, we welcome the opportunity to explore topics including integrated DNA–RNA–LNP development, IIT strategies, CMC planning, and technology transfer.

We look forward to meeting you in Boston this July！